This study will determine the efficacy and safety of combination therapy with divalproex and lithium for treating mania in people with rapid cycling bipolar disorder and a substance abuse disorder.
Longitudinal Evaluation of the Efficacy and Safety of Divalproex and Lithium in Dual Diagnosis Bipolar Rapid Cycling: This study recruits males and females age 18 and older who currently meet diagnostic criteria for rapid cycling bipolar disorder (type I or II) and who have met the criteria for substance abuse or dependence of cocaine, marijuana and/or alcohol within the past six months. Patients are initially stabilized on dual therapy of lithium and depakote and then randomly assigned to double-blind treatment with either lithium monotherapy or continued dual therapy. Patients remain in the study for six months or until they experience a relapse. Patients in this study are required to bring a friend or family member to all study visits as well as attend chemical dependency services. This study is sponsored by the NIMH. Subjects receive study-related care at no cost.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
31
Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.
Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.
Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.
University Hospitals of Cleveland
Cleveland, Ohio, United States
Time to Treatment for Emerging Symptoms of a Mood Relapse
A relapse is a return to either a depressive, manic, hypomanic or mixed episode after a period of not have any symptoms.
Time frame: Up to 6 months
Time to Treatment for Emerging Symptoms of a Manic/Hypomanic/Mixed Episode
Time frame: Up to 6 months
Time to Treatment for Emerging Symptoms of a Depressive Episode
Time frame: Up to 6 months
Change in Rate of Alcohol Use Disorders After Open-label Treatment With Lithium and Divalproex
Number of subjects who no longer met criteria for active abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex
Time frame: Baseline to Month 6
Change in Rate of Cannabis Use Disorders After Open-label Treatment With Lithium and Divalproex
Number of subjects who no longer met criteria for active cannabis abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex
Time frame: Baseline to Month 6
Change in Rate of Cocaine Use Disorders After Open-label Treatment With Lithium and Divalproex
Number of subjects who no longer met criteria for active cocaine abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex
Time frame: Baseline to Month 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.